公告称，报告期内，公司战略业务稳健增长，F端及B端战略业务收入同比增长19.7%；其中，F端取得11.15亿元，同比增长3.4%(2023H1：10.78亿元)，B端取得收入7.13亿元，同比增长58.8%(2023H1：4.49亿元)。Ping An Health (01833) rose more than 5% after its performance, and as of the press release, it rose 5.18% to HKD 10.96, with a turnover of HKD 18.0008 million.
According to the Zhitong Finance APP, Ping An Health (01833) rose more than 5% after its performance, and as of the press release, it rose 5.18% to HKD 10.96, with a turnover of HKD 18.0008 million.
In terms of news, Ping An Health released unaudited interim results for the six-month period ending June 30, 2024. The group achieved revenue of CNY 2.093 billion during the period, gross profit of CNY 0.674 billion, and a net profit attributable to shareholders of CNY 56.648 million. In the same period last year, the net loss attributable to shareholders was CNY 0.245 billion, turning losses into profit year-on-year, with basic earnings per share of CNY 0.05.
According to the announcement, the company's strategic business grew steadily during the reporting period, with a 19.7% year-on-year increase in revenue from the F-end and B-end strategic business. Among them, the F-end achieved revenue of CNY 1.115 billion, a year-on-year increase of 3.4% (1.078 billion yuan in 2023 H1), and the B-end achieved revenue of CNY 0.713 billion, a year-on-year increase of 58.8% (0.449 billion yuan in 2023 H1).